CoChat

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment

Open access
Yokote, Koutaro, Yamashita, Shizuya, Arai, Hidenori, Araki, Eiichi, Suganami, Hideki, Ishibashi, Shun · 2019 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Abstract

Pemafibrate (K-877) is a novel selective peroxisome proliferator-activated receptor-α modulator (SPPARMα) with a favorable benefit-risk balance. Previous clinical trials of pemafibrate used stringent exclusion criteria related to renal functions. Therefore, we investigated its safety and efficacy in a broader range of patients, including those with chronic kidney disease (CKD). In this multicenter, single-arm, open-label, phase III trial, 0.2–0.4 mg/day pemafibrate was administered for 52 weeks to 189 patients with hypertriglyceridemia and an estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2 on statin or regardless of eGFR when statin was not administered. Post-hoc analyses were performed on subgroups stratified by baseline eGFR. Triglyceride levels decreased by 45.9% at week 52 (last-observation-carried-forward). These reductions were not correlated with baseline eGFR. The eGFR < 30 mL/min/1.73 m2 subgroup showed the greatest reduction in chylomicron, very low-density lipoprotein, small low-density lipoprotein cholesterol levels, and an increase in high-density lipoprotein cholesterol levels. The incidences of adverse events and adverse drug reactions were 82.0% and 31.7%, respectively, and these were not associated with baseline eGFR. In CKD patients, pemafibrate blood concentrations were not elevated. Pemafibrate showed a good safety profile and efficacy in correcting lipid abnormalities in a broad range of patients, including those with CKD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms20030706

Cites

48 of 49 references verified1 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow chart of included and excluded patients.
Figure 1 Flow chart of included and excluded patients.CC BY · PubMed Central
Figure 2 Time course of fasting serum TG levels. Data are presented as means ± SD. TG, triglyceride; LOCF, last-observation-carried-forward; SD, standard deviation.
Figure 2 Time course of fasting serum TG levels. Data are presented as means ± SD. TG, triglyceride; LOCF, last-observation-carried-forward; SD, standard deviation.CC BY · PubMed Central
Figure 3 Subgroup analysis for percent change of TG from baseline at week 52 (LOCF). Data of percent change of TG are presented as means (95% CI), and data of baseline TG are presented as means (SD). TG, triglyceride; LOCF, last-observation-carried-forward; SD, standard deviation; CI, confidence interval; BMI, body mass index; DM, diabetes mellitus; Mets, metabolic syndrome.
Figure 3 Subgroup analysis for percent change of TG from baseline at week 52 (LOCF). Data of percent change of TG are presented as means (95% CI), and data of baseline TG are presented as means (SD). TG, triglyceride; LOCF, last-observation-carried-forward; SD, standard deviation; CI, confidence interval; BMI, body mass index; DM, diabetes mellitus; Mets, metabolic syndrome.CC BY · PubMed Central
Figure 4 Time course of fasting serum TG levels by baseline eGFR category. Baseline eGFR categories are as follows: G1, eGFR ≥ 90 mL/min/1.73 m2; G2, eGFR ≥ 60 and <90 mL/min/1.73 m2; G3a–G3b, eGFR ≥ 30 and <60 mL/min/1.73 m2; and G4–G5, eGFR < 30 mL/min/1.73 m2. Data are presented as means ± standard deviation. TG, triglyceride; eGFR, estimated glomerular filtration rate; LOCF, last-observation-carried-forward.
Figure 4 Time course of fasting serum TG levels by baseline eGFR category. Baseline eGFR categories are as follows: G1, eGFR ≥ 90 mL/min/1.73 m2; G2, eGFR ≥ 60 and <90 mL/min/1.73 m2; G3a–G3b, eGFR ≥ 30 and <60 mL/min/1.73 m2; and G4–G5, eGFR < 30 mL/min/1.73 m2. Data are presented as means ± standard deviation. TG, triglyceride; eGFR, estimated glomerular filtration rate; LOCF, last-observation-carried-forward.CC BY · PubMed Central
Figure 5 Time course of the levels of eGFR (A), serum creatinine (B), and CK (C) by baseline eGFR category. Baseline eGFR categories are as follows: G1, eGFR ≥90 mL/min/1.73 m2; G2, eGFR ≥60 and <90 mL/min/1.73 m2; G3a–G3b, eGFR ≥30 and <60 mL/min/1.73 m2; and G4–G5, eGFR <30 mL/min/1.73 m2. Data are presented as means ± SD. eGFR, estimated glomerular filtration rate; CK, creatine kinase; SD, standard deviation.
Figure 5 Time course of the levels of eGFR (A), serum creatinine (B), and CK (C) by baseline eGFR category. Baseline eGFR categories are as follows: G1, eGFR ≥90 mL/min/1.73 m2; G2, eGFR ≥60 and <90 mL/min/1.73 m2; G3a–G3b, eGFR ≥30 and <60 mL/min/1.73 m2; and G4–G5, eGFR <30 mL/min/1.73 m2. Data are presented as means ± SD. eGFR, estimated glomerular filtration rate; CK, creatine kinase; SD, standard deviation.CC BY · PubMed Central
Figure 6 Plasma concentrations of pemafibrate after repeated-dose administration. Baseline eGFR categories are as follows: G1, eGFR ≥ 90 mL/min/1.73 m2; G2, eGFR ≥ 60 and <90 mL/min/1.73 m2; G3a–G3b, eGFR ≥ 30 and <60 mL/min/1.73 m2; G4–G5, eGFR < 30 mL/min/1.73 m2. eGFR, estimated glomerular filtration rate.
Figure 6 Plasma concentrations of pemafibrate after repeated-dose administration. Baseline eGFR categories are as follows: G1, eGFR ≥ 90 mL/min/1.73 m2; G2, eGFR ≥ 60 and <90 mL/min/1.73 m2; G3a–G3b, eGFR ≥ 30 and <60 mL/min/1.73 m2; G4–G5, eGFR < 30 mL/min/1.73 m2. eGFR, estimated glomerular filtration rate.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 82

Metadata

Authors
Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S.
Affiliations
  • Chiba University (JP)
  • Rinku General Medical Center (JP)
  • National Center for Geriatrics and Gerontology (JP)
  • Kumamoto University (JP)
  • Kowa (Japan) (JP)
  • Jichi Medical University (JP)
Corresponding author
Yokote, Koutaro
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2019-02-06
Volume
20
Issue
3
Pages
706
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2913672551
Cited by
79
References
48
Citations by year
2026: 4 · 2025: 8 · 2024: 12 · 2023: 14 · 2022: 9 · 2021: 12 · 2020: 10 · 2019: 9
FWCI
3.31
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Kowa Company
  • Japan Society for the Promotion of Science (17K19643, 17H04201, 17H02100, 18K08482)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
pemafibrate, PPARα modulator, chronic kidney disease, renal dysfunction, hypertriglyceridemia, dyslipidemia, triglyceride lowering, lipid-lowering therapy, drug safety, adverse drug reactions
MeSH terms
Aged, Benzoxazoles, Butyrates, Female, Humans, Kidney Function Tests, Lipids, Male, Middle Aged, Biomarkers, Treatment Outcome, PPAR alpha, Dyslipidemias, Renal Insufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment. https://app.cochat.ai/papers/10.3390/ijms20030706
The paper
Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2019). Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms20030706

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.